LGP5 NPV
Risk adjusted net present value: What is the current valuation of Novo Nordisk’s NNC0519-0130?
NNC0519-0130 is commercialized by Novo Nordisk, with a leading Phase II program in Type 2 Diabetes. According to Globaldata, it…
Risk adjusted net present value: What is the current valuation of AstraZeneca’s AZD-9574?
AZD-9574 is a small molecule commercialized by AstraZeneca, with a leading Phase II program in Vaginal Cancer. According to Globaldata,…
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Sabestomig?
Sabestomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase II program in Non-Small Cell Lung Carcinoma. According…
Risk adjusted net present value: What is the current valuation of AbbVie’s ABBV-400?
ABBV-400 is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase II program in Metastatic Colorectal Cancer. According…
Risk adjusted net present value: What is the current valuation of Merck’s MK-1084?
MK-1084 is a small molecule commercialized by Merck, with a leading Phase I program in Metastatic Colorectal Cancer. According to…